Houston – October 02, 2026 -- Researchers at Rice University, backed by the Rice Biotech Launch Pad, have developed an implantable device that produced therapeutic monoclonal antibodies continuously for one year across multiple preclinical models, with the platform now advancing toward human trials through biotech company Duracyte.